Empowering women worldwide
We put women at the center of our product development and health education efforts. We dare to assist women during some of the most important chapters of their lives, sharing our knowledge and treatments throughout the world.
To optimize the development of treatments, we work with both private and public organizations worldwide. One example of this is our collaboration with the International Consortium for Emergency Contraception (ICEC) and the European Consortium for Emergency Contraception (ECEC) whose mission is to expand knowledge about and access to Emergency Contraception (EC) in European countries and to promote the standardization of EC service delivery in the European context.
Indeed, our devotion to improving lives and empowering patients has shaped the way we do business from the very beginning. It has also been the inspiration for our socially conscious approach to women’s healthcare.
Through our initiatives, we aim to expand further women's access to safe, effective and modern methods of contraception and reproductive health services.
We have also developed patient information leaflets - in the form of drawings - to enable women with low levels of literacy in developing countries to understand how to use emergency contraception.
We have endeavored to obtain regulatory approval for emergency contraceptive products throughout the world, including in countries where there may be obstacles to registration of such products. Through our efforts, emergency contraception is now available to millions of women who otherwise might not have had access to this type of method
Emergency contraception, or post-coital contraception, refers to methods of contraception that can be used to prevent pregnancy in the first few days after intercourse. It is intended for emergency use following unprotected intercourse, contraceptive failure or misuse (such as forgotten pills or torn condoms), rape or coerced sex*.
* World Health Organization – FactSheet N°244- July 2012
However, there is still a long way to go. Despite efforts, emergency contraception is still widely underused.
In Europe, for example, where women’s rights and access to information are amongst the most developed in the world, a survey* showed that fewer that 25% of women had used emergency contraception after they had unprotected sex, mainly because they did not believe they were at risk of pregnancy.
*Sex and emergency contraception in Europe: beliefs, practices and attitudes of women,’ download this BVA European survey conducted on 7 170 fertile women between the ages of 16 and 45.
Our innovative treatments in women’s health
Our women’s health portfolio includes two leading proprietary drugs for emergency contraception:
• NorLevo® (levonorgestrel, 1.5mg, tablet)
• ellaOne ® (ulipristal acetate, 30 mg, tablet)
Emergency contraception can best prevent pregnancies when used soon after sexual intercourse. It is also commonly known as the ‘morning-after pill’ or ‘day-after pill’.
Our portfolio also includes treatments for genital herpes, uterine fibroids, intimate health and contraception.
The continuous pursuit of excellence for the wellbeing of women worldwide
We are extremely active in research and innovation, to ensure we stay one step ahead in providing treatments in the areas of women’s health.
At HRA Pharma, we strive for innovation seriously. We make it our business to continuously push the boundaries of women’s health treatments. We ensure our treatments are relevant, ground breaking and adapted to suit the needs of women worldwide.
At HRA Pharma we have made women’s health our mission. For us, it is about more than just business.
Our teams are on-hand to answer any questions you may have and to provide you with medical information about our products.